Omalizumab Combined with Cyclosporine for the Treatment and Management of Refractory Urticarial Vasculitis

Urticarial vasculitis (UV) is a clinicopathologic entity characterized by urticarial lesions disclosing histopatho logically leukocytoclastic vasculitis, mainly of postcapillary venules. A 61-year-old woman with a four-month history of widespread, pruritic urticarial lesions was diagnosed with urticarial vasculitis. The patient received a subcutaneous injection of Omalizumab (300 mg) every 28 days, combined with oral Cyclosporine (3 mg/kg/day). Significant clinical improvement was noted within five days post-treatment. This case highlights the difficulties in treating refractory urticarial vasculitis while demonstrating the successful use of Omalizumab plus Cyclosporine, providing a viable treatment option for similar patients.